SCHEDULE: Van Herk Investments Opposes ProQR Share Capital Proposals

Van Herk Investments B.V. announced its intention to vote against key share capital increase and authorization proposals at ProQR Therapeutics N.V.'s upcoming Annual General Meeting, citing concerns over potential dilution and governance.

Summary

• Van Herk Investments B.V. (VHI) and its affiliates have formally stated their intention to vote against agenda items 7, 8, and 9 at ProQR Therapeutics N.V.'s 2026 Annual General Meeting (AGM).
• These agenda items concern a proposed increase in authorized share capital, a standing authorization for the board to issue shares, and authorization for the board to acquire shares.
• VHI argues that these proposals would grant the Board excessive discretion over the company's capital structure, potentially leading to substantial dilution of existing shareholders without adequate justification or safeguards.
• The group also highlighted concerns about the lack of a specific identified need for such broad authorizations and stated that the proposals are not in line with Dutch market practices.
• VHI believes the Board's current governance, including the chairman's tenure and multiple board positions, does not inspire confidence for such significant capital authority.
• Institutional Shareholder Services Inc. (ISS) has also reportedly issued negative recommendations on similar proposals.
• VHI is engaging a shareholder engagement advisor and has retained counsel, considering legal proceedings to protect shareholder interests.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant shareholder opposition and concerns about dilution and governance, indicating potential conflict and instability.

Negatives

• Van Herk Investments B.V. and its affiliates intend to vote against agenda items 7, 8, and 9 at the 2026 AGM.
• Concerns raised include the potential for substantial dilution of existing shareholders (up to 61%) without further shareholder approval or pre-emptive rights.
• The Board has not identified a specific transaction, financing need, or strategic justification for the requested broad authorizations.
• The proposals are seen as lacking meaningful limitations, safeguards, or conditions, and are not aligned with Dutch market practices.
• Existing governance concerns, including the chairman's tenure and multiple board positions, are cited as reasons for a lack of confidence in the Board's oversight.
• The potential for the Board to opt out of Nasdaq's 20% Rule (Rule 5635(d)) without shareholder oversight is a significant concern.
• The elimination of pre-emptive rights could allow the Board to issue shares to selected parties, including affiliates, without offering existing shareholders pro rata participation.
• The combination of unlimited share issuance and repurchase authority gives the Board effective control over the capital structure, with a risk of value-destructive use.
• The potential for dilution may restrict the ability of shareholders to subject the company's governance to judicial review under Dutch law.

Risks

• Substantial dilution of existing shareholders (up to 61%) without further shareholder approval or pre-emptive rights.
• Granting the Board excessive discretion over the company's capital structure.
• Potential for the Board to opt out of Nasdaq's 20% Rule (Rule 5635(d)) without shareholder oversight.
• The elimination of pre-emptive rights could allow the Board to issue shares to selected parties, including affiliates, without offering existing shareholders pro rata participation.
• Risk of value-destructive or opportunistic use of broad share issuance and repurchase authority.
• The potential for dilution may restrict the ability of shareholders to subject the company's governance to judicial review under Dutch law.
• The Board's current governance structure may not provide adequate independent scrutiny for capital decisions.

Future Outlook

Van Herk Investments B.V. and its affiliates intend to review their investment in ProQR Therapeutics N.V. on a continuing basis and may take various actions, including engaging with management, communicating with other shareholders, proposing changes to capitalization or governance, initiating legal proceedings, or adjusting their shareholdings.

Management Comments

• The combined effect of agenda items 7, 8 and 9 would grant the Board overly broad discretion over the Issuer's capital structure.
• The proposals could result in substantial dilution of existing shareholders without further shareholder approval or pre-emptive rights.
• The Board has not identified a specific transaction, financing need or other demonstrated justification for the requested authorizations.
• The proposed authorizations lack meaningful limitations, safeguards or conditions.
• The breadth of the requested authority is not appropriate in light of the Issuer's performance and existing governance concerns.
• Generic references to 'flexibility' or 'business opportunities' are insufficient to justify such far-reaching powers.
• Shareholders are effectively being asked to accept substantial dilution and broad buyback authority on faith alone, which is not justified, particularly in light of the Company's weak performance and lack of clinical progress.
• The Board should first address its governance shortcomings before seeking expanded capital authority of this magnitude.

Industry Context

StockSavvy.ai notes that this filing highlights a significant shareholder activism event within the biotechnology sector, where control over capital structure and dilution are critical concerns for investors, especially concerning companies with unproven clinical progress.

Comparison to Industry Standards

• The filing states that a blank authorization to increase outstanding share capital by up to 156% without meaningful limitations is not in line with market practice for entities listed in the Netherlands.
• The 20% Rule (Nasdaq Listing Rule 5635(d)), which generally requires shareholder approval for issuances exceeding 20% of shares outstanding, is presented as a key protection for shareholders against unrestricted dilution, which ProQR, as a foreign private issuer, can opt out of.
• ISS (Institutional Shareholder Services Inc.) has reportedly issued negative voting recommendations on similar share-capital-related proposals, indicating a broader concern among institutional governance advisors regarding such broad authorizations.

Corporate Governance

Legal Proceedings

• The Reporting Persons have retained counsel and are evaluating the initiation of legal proceedings against the Issuer, members of the Board, and/or certain officers to protect their rights and interests and those of other stockholders.
• Any such proceedings may seek declaratory, injunctive, equitable, monetary, and/or other relief.

Related Party Transactions

• Concerns are raised that the Board could use the proposed authority to issue shares to its own members or affiliates without further shareholder approval, especially with the elimination of pre-emptive rights.

Stakeholder Impact

• Shareholders: Potential for substantial dilution of ownership stake and voting power; potential restriction of rights to judicial review under Dutch law.
• Board of Directors: Facing opposition to proposed capital authorities and potential legal action.
• Management: Subject to potential legal proceedings and scrutiny over governance and strategic decisions.

Next Steps

• Van Herk Investments B.V. will vote against agenda items 7, 8, and 9 at the 2026 AGM.
• VHI is engaging a shareholder engagement advisor to communicate its rationale to other shareholders.
• The Reporting Persons are evaluating the initiation of legal proceedings against the Issuer, members of the Board, and/or certain officers.
• The Reporting Persons intend to review their investment in the Issuer on a continuing basis and may take further actions.

Key Dates

Recommendation

While Van Herk's opposition highlights significant governance and dilution concerns, the filing is an amendment to a Schedule 13D, indicating an ongoing investment and potential for future actions rather than an immediate catalyst for a strong buy or sell. The outcome of the AGM and any potential legal proceedings will be critical. For now, a 'hold' position allows investors to monitor developments.

Keywords

ProQR Therapeutics, Van Herk Investments, Schedule 13D, Share Capital, Shareholder Meeting, Dilution, Corporate Governance, AGM, Netherlands, SEC Filing